Sustainability – a valuable opportunity for the pharmaceutical industryThe pharmaceutical industry has a substantial impact on the environment and, when it comes to sustainability, it has Share XSustainability – a valuable opportunity for the pharmaceutical industryhttps://pharmaphorum.com/views-and-analysis/sustainability-opportunity-pharmaceutical-industry/
Pfizer and the UK cancer landscape: the pharmaphorum podcastPfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK Share XPfizer and the UK cancer landscape: the pharmaphorum podcast
Future proofing the UK’s research ecosystem in the face of global changeThe UK is a powerhouse of clinical research but maintaining that leading position – and all the benefits Share XFuture proofing the UK’s research ecosystem in the face of global changehttps://pharmaphorum.com/r-d/views-analysis-r-d/future-proofing-the-uks-research-ecosystem-in-the-face-of-global-change/
15 pharma trends for 2020Real world evidence, patient centricity and new digital experiences are among the top 15 trends set to change Share X15 pharma trends for 2020https://pharmaphorum.com/views-analysis-digital/15-pharma-trends-for-2020/
How does prevalence affect pricing of rare disease drugs?New research from CRA looks at the relationship between rarity of a disease and the price countries are Share XHow does prevalence affect pricing of rare disease drugs?https://pharmaphorum.com/views-analysis-market-access/prevalence-pricing-rare-disease-drugs/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
Deep Dive: Patient EngagementPatient engagement has moved from a lofty goal to a tangible part of most pharma companies’ businesses – Share XDeep Dive: Patient Engagementhttps://pharmaphorum.com/views-and-analysis/deep-dive-patient-engagement/
Q&A: Avacta’s Amrik Basran on immunotherapyDr Amrik Basran from Avacta explains the current state of cancer immunotherapy and the challenges of moving into Share XQ&A: Avacta’s Amrik Basran on immunotherapyhttps://pharmaphorum.com/views-analysis-oncology/avactas-amrik-basran-on-immunotherapy/
Harnessing the digital transformation of the drug development pathwayWe have the evidence base to support the digital transformation of clinical trials – what we need now Share XHarnessing the digital transformation of the drug development pathwayhttps://pharmaphorum.com/views-analysis-digital/harnessing-the-digital-transformation-of-the-drug-development-pathway/
